GNRH1 and posterior cortical atrophy: In this study, men with incident PCa undergoing endocrine treatment (i.e., antiandrogens (AAs), orchiectomy, gonadotropin-releasing hormone (GnRH) agonists or combined AA/GnRH agonist treatment) had an increased standardised incidence rate of 1.66 (95% CI 1.57–1.76) for HF compared with that expected based on the Swedish male background population without pre-existing circulatory disease.30 Unlike our study, they also found an increased risk of HF in the men who received curative treatment.